HU6

HU6 (dinifedriton; 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole; CAS 2231311-68-3) is a first-in-class controlled metabolic accelerator (CMA) developed by Rivus Pharmaceuticals as an oral prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP). The compound is designed to undergo hepatic bioactivation to release DNP within the liver, thereby increasing proton leak across the inner mitochondrial membrane via activation of the adenine nucleotide translocase (ANT) channel. This controlled mitochondrial uncoupling increases substrate oxidation, preferentially consuming hepatic and systemic fat stores while reducing reactive oxygen species production and preserving lean skeletal muscle mass. The prodrug strategy addresses the principal limitation of DNP itself, which was withdrawn from clinical use in 1938 owing to a narrow therapeutic index characterized by dose-dependent hyperthermia, cataracts, agranulocytosis, and death at supratherapeutic exposures. By restricting DNP release to the hepatic first-pass compartment and minimizing systemic peak concentrations, HU6 achieves a substantially wider therapeutic index than the parent uncoupler while retaining its metabolic efficacy.

The scientific foundation for HU6 derives from the seminal work of Perry et al. (2015), published in Science, demonstrating that a controlled-release mitochondrial protonophore (CRMP) formulation of DNP reversed diabetes, hypertriglyceridemia, hepatic steatosis, and liver fibrosis in rat models of metabolic syndrome and nonalcoholic steatohepatitis (NASH) without systemic toxicity [1]. This proof of concept was extended to dysmetabolic nonhuman primates by Goedeke et al. (2019), who reported that CRMP produced 20 to 30 percent reductions in fasting plasma triglycerides and low-density lipoprotein cholesterol with concurrent resolution of hepatic steatosis [2]. Rivus Pharmaceuticals was founded in 2019 to advance these findings into clinical development, selecting HU6 as the lead clinical candidate from a portfolio of controlled metabolic accelerator assets.

Three Phase 2 clinical trials have been completed or are in progress. The first Phase 2a trial in 80 patients with nonalcoholic fatty liver disease (NAFLD) and body mass index (BMI) of 28 to 45 kg/m2 demonstrated dose-dependent reductions in liver fat content of 26.8 to 35.6 percent from baseline over 61 days at doses of 150, 300, and 450 mg once daily, compared with a 5.4 percent increase in the placebo group, with concurrent body weight reductions of 0.52 to 2.75 kg; results were published in The Lancet Gastroenterology and Hepatology [3]. The Phase 2a HuMAIN trial in 66 patients with obesity-related heart failure with preserved ejection fraction (HFpEF) met its primary endpoint of body weight reduction (2.86 kg versus placebo over 19 weeks), with fat-selective weight loss preserving skeletal muscle mass and producing significant improvements in left ventricular ejection fraction (3.76 percent) and end-systolic volume; results were published in JAMA Cardiology [4, 5]. The Phase 2 M-ACCEL trial in 228 patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F2 to F3 demonstrated statistically significant liver fat reductions of 27.0 to 31.2 percent versus 6.7 percent with placebo over 26 weeks, with approximately 50 to 58 percent of treated patients achieving the clinically meaningful threshold of 30 percent or greater liver fat reduction associated with MASH resolution and fibrosis improvement [6].

Across all three trials, HU6 demonstrated a favorable safety profile with no treatment-related serious adverse events in a cumulative safety database exceeding 500 patients. The most commonly reported treatment-emergent adverse events were flushing (32 percent in early trials, reduced in later formulations), diarrhea (25 percent), and palpitations (12 percent), with discontinuation rates due to adverse events below 5 percent. Gastrointestinal adverse event rates in the M-ACCEL trial were comparable to placebo (14 versus 16 percent). The compound is currently advancing through the AMPLIFY Phase 2 trial for MASH with plans for late-stage clinical development. This monograph reviews the chemistry, mechanism of action, pharmacokinetics, preclinical and clinical evidence, safety profile, and comparative positioning of HU6 against five alternative therapeutic approaches to MASH and metabolic liver disease.